Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting

Despite significant progress in the prevention of chemotherapy-induced nausea and vomiting (CINV) with the introduction of new antiemetic agents, 30–50% of patients receiving moderately or highly emetogenic chemotherapy (MEC or HEC) and guideline directed prophylactic antiemetics develop breakthroug...

Descripción completa

Detalles Bibliográficos
Autor principal: Navari, Rudolph M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4573228/
https://www.ncbi.nlm.nih.gov/pubmed/26421294
http://dx.doi.org/10.1155/2015/595894

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4573228/
https://www.ncbi.nlm.nih.gov/pubmed/26421294
http://dx.doi.org/10.1155/2015/595894

Ejemplares similares